Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Terminated
Trial end date:
2018-06-05
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in
patients with locally advanced or metastatic solid tumors, who have no available therapy
likely to convey clinical benefit.
This study will examine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and
preliminary efficacy of RXDX 106.